>>”>Jerusalem, 30 April, 2026 (TPS-IL) — Israeli drugmaker RedHill Biopharma said new test results showed its experimental Crohn’s disease treatment RHB-204 worked as well as an earlier version of the drug in killing bacteria linked to the illness.
The Tel Aviv-based company said the treatment targets MAP, a bacterium some researchers believe may contribute to Crohn’s disease. RedHill said the new version uses lower amounts of two ingredients while keeping the same effectiveness, which could help reduce side effects.
The company plans to begin a Phase 2 clinical trial in Crohn’s patients who test positive for the bacteria. Earlier Phase 3 results for RedHill’s RHB-104 treatment showed improved remission rates compared to standard care alone.